CompletedPhase 3NCT02920008
Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia
Studying Acute promyelocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Astex Pharmaceuticals, Inc.
- Principal Investigator
- Harold N Keer, MD, PhDAstex Pharmaceuticals, Inc.
- Intervention
- guadecitabine(drug)
- Enrollment
- 302 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2020
Study locations (30)
- University of Southern California, Los Angeles, California, United States
- The University of Chicago Medical Center, Chicago, Illinois, United States
- Franciscan Research Center, Indianapolis, Indiana, United States
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
- University of New Mexico School of Medicine, Albuquerque, New Mexico, United States
- Roswell Park Cancer Institute, Buffalo, New York, United States
- Weill Cornell Medical College, New York, New York, United States
- Duke Cancer Institute, Durham, North Carolina, United States
- University of Oklahoma Medical Center, Oklahoma City, Oklahoma, United States
- Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
- Temple University Hospital, Philadelphia, Pennsylvania, United States
- Vanderbilt University Medical Center, Nashville, Tennessee, United States
- Baylor Research Institute, Dallas, Texas, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- West Virginia University Hospitals, Inc., Morgantown, West Virginia, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02920008 on ClinicalTrials.govOther trials for Acute promyelocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07563179Bugitinib Combined With Venetoclax and Cytarabine in Relapsed/Refractory Acute Myeloid LeukemiaShenzhen University General Hospital
- RECRUITINGPHASE3NCT07504458Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic LeukemiaQuetzal Therapeutics
- RECRUITINGPHASE3NCT07223814Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)Stichting Hemato-Oncologie voor Volwassenen Nederland
- ACTIVE NOT RECRUITINGNANCT07187505Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic LeukemiaAnhui Medical University
- RECRUITINGPHASE3NCT07503730Early Use of Realgar-Indigo Naturalis Formula (RIF) Combined With All-trans Retinoic Acid (ATRA) for Treating Acute Promyelocytic Leukemia (APL).First Affiliated Hospital Xi'an Jiaotong University
- ENROLLING BY INVITATIONNANCT06697327Daunorubicin + Cytarabine + Venetoclax in de Novo AMLAnhui Medical University
- RECRUITINGPHASE1NCT06313437Revumenib in Combination With 7+3 + Midostaurin in AMLRichard Stone, MD
- RECRUITINGPHASE3NCT06578247Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AMLDaiichi Sankyo